Form 4: Tectonic Therapeutic CEO Disposes Shares for Tax Obligations Following RSU Vesting

Tectonic Therapeutic, Inc. CEO Alise Reicin reported a disposition of 859 common shares at $19.81 each to cover tax withholding obligations related to vested restricted stock units.

Summary

• Alise Reicin, Chief Executive Officer and Director of Tectonic Therapeutic, Inc. (TECX), reported a transaction on June 20, 2025.
• The transaction involved the disposition of 859 shares of Tectonic Therapeutic Common Stock.
• The shares were disposed of at a price of $19.81 per share.
• This disposition was categorized as a withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations.
• The tax obligations arose from the non-reportable vesting and settlement of restricted stock units (RSUs) that were granted on December 4, 2024.
• Following this transaction, Alise Reicin directly beneficially owns 213,485 shares of Common Stock.
• Additionally, Alise Reicin indirectly beneficially owns 124,530 shares of Common Stock through the Reicin-Boiarsky Family Trust, where her spouse is a co-trustee.

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction (disposition of shares for tax withholding) related to executive compensation, which is a neutral event for the company's operational performance or strategic outlook.

Positives

• The transaction indicates the vesting of restricted stock units (RSUs) for the CEO, which is a positive event for the executive as it represents a realization of compensation.

Negatives

• A disposition of 859 common shares by the CEO occurred, although this was specifically for tax withholding purposes rather than a direct sale for personal gain.

Risks

• NA

Future Outlook

This SEC Form 4 filing is a report of an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• "The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units granted on December 4, 2024."

Industry Context

This Form 4 filing details a standard insider transaction related to executive compensation and tax obligations, which is a common and routine occurrence across all industries for publicly traded companies. It does not provide specific insights into broader biotechnology or pharmaceutical industry trends.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Shares are held indirectly by the Reicin-Boiarsky Family Trust, where the Reporting Person's spouse is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership due to tax withholding, which is a routine event and not indicative of a lack of confidence in the company by the CEO.

Next Steps

• NA

Key Dates

Keywords

Tectonic Therapeutic, TECX, Alise Reicin, SEC Form 4, Insider Transaction, Stock Disposition, Restricted Stock Units, RSU Vesting, Tax Withholding, Executive Compensation